JOP20220034A1 - مركبات [1، 2، 4] تريازولو [1، 5-جـ] كوينازولين-5-أمين - Google Patents

مركبات [1، 2، 4] تريازولو [1، 5-جـ] كوينازولين-5-أمين

Info

Publication number
JOP20220034A1
JOP20220034A1 JOP/2022/0034A JOP20220034A JOP20220034A1 JO P20220034 A1 JOP20220034 A1 JO P20220034A1 JO P20220034 A JOP20220034 A JO P20220034A JO P20220034 A1 JOP20220034 A1 JO P20220034A1
Authority
JO
Jordan
Prior art keywords
compounds
quinazolin
triazolo
preparing
pharmaceutical compositions
Prior art date
Application number
JOP/2022/0034A
Other languages
English (en)
Inventor
Buchmann Bernd
Bothe Ulrich
GUTCHER Ilona
Bader Benjamin
Gunther Judith
Lefranc Julien
Baumann Daniel
ST?CKIGT Detlef
Michael Meier Robin
B?Hme Stephan
Anthony Herbert Simon
Kober Christina
R?Se Lars
Zorn Ludwig
Gorj?N?Cz M?Ty?S
Platten Michael
Schmees Norbert
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of JOP20220034A1 publication Critical patent/JOP20220034A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات [1، 2، 4] تريازولو [1، 5-جـ] كوينازولين-5-أمين بالصيغة العامة (I): (I) حيث R1، R2، R3، R4، R5، R6، R7 وR8 كما هي موضحة ومحددة في هذه الوثيقة، بطرق لتحضير المركبات المذكورة، بمركبات وسيطة مفيدة في تحضير المركبات المذكورة، بتراكيب وتوليفات صيدلانية تشتمل على المركبات المذكورة، وباستخدام المركبات المذكورة في تصنيع تراكيب صيدلانية مستخدمة في العلاج أو الوقاية من الأمراض، ولا سيما السرطان أو حالات مرضية مقترنة باختلال الاستجابات المناعية وغيرها من الاضطرابات المصاحبة لتأشير AHR الشاذ، كعامل وحيد أو بشكل مؤتلف مع مكونات نشطة أخرى
JOP/2022/0034A 2019-08-12 2020-08-10 مركبات [1، 2، 4] تريازولو [1، 5-جـ] كوينازولين-5-أمين JOP20220034A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19191299 2019-08-12
EP20167707 2020-04-02
PCT/EP2020/072377 WO2021028382A1 (en) 2019-08-12 2020-08-10 [1,2,4]triazolo[1,5-c]quinazolin-5-amines

Publications (1)

Publication Number Publication Date
JOP20220034A1 true JOP20220034A1 (ar) 2023-01-30

Family

ID=72243077

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0034A JOP20220034A1 (ar) 2019-08-12 2020-08-10 مركبات [1، 2، 4] تريازولو [1، 5-جـ] كوينازولين-5-أمين

Country Status (19)

Country Link
US (1) US20230113037A1 (ar)
EP (1) EP4013508A1 (ar)
JP (1) JP2022544952A (ar)
KR (1) KR20220045978A (ar)
CN (1) CN114466850A (ar)
AU (1) AU2020328154A1 (ar)
BR (1) BR112022001628A2 (ar)
CA (1) CA3150544A1 (ar)
CO (1) CO2022001257A2 (ar)
CR (1) CR20220064A (ar)
DO (1) DOP2022000031A (ar)
EC (1) ECSP22009803A (ar)
GE (1) GEP20247611B (ar)
IL (1) IL290445A (ar)
JO (1) JOP20220034A1 (ar)
MX (1) MX2022001803A (ar)
PE (1) PE20220967A1 (ar)
TW (1) TW202126655A (ar)
WO (1) WO2021028382A1 (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230167103A1 (en) 2020-04-24 2023-06-01 Bayer Aktiengesellschaft Substituted aminothiazoles as dgkzeta inhibitors for immune activation
WO2022049253A1 (en) * 2020-09-07 2022-03-10 Bayer Aktiengesellschaft Substituted n-heteroaryl-n-pyridinylacetamides as p2x4 modulators
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
CN114621236A (zh) * 2022-04-25 2022-06-14 河南湾流生物科技有限公司 一种喹啉类饲料添加剂的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358964B1 (en) * 2000-07-26 2002-03-19 King Pharmaceuticals Research And Development, Inc. Adenosine, A3 receptor modulators
JP2008520746A (ja) * 2004-11-22 2008-06-19 キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド アデノシンａ３受容体アンタゴニストを用いる癌及びｈｉｆ−１が介在する疾患の促進的治療
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
EP2598138B1 (en) 2010-07-27 2020-05-06 Trustees of Boston University Aryl hydrocarbon receptor (ahr) modifiers as novel cancer therapeutics
WO2020102506A1 (en) * 2018-11-14 2020-05-22 The Broad Institute, Inc. Aryl hydrocarbon receptor (ahr) activator compounds as cancer therapeutics

Also Published As

Publication number Publication date
DOP2022000031A (es) 2022-03-15
EP4013508A1 (en) 2022-06-22
CA3150544A1 (en) 2021-02-18
CN114466850A (zh) 2022-05-10
TW202126655A (zh) 2021-07-16
JP2022544952A (ja) 2022-10-24
CO2022001257A2 (es) 2022-03-08
ECSP22009803A (es) 2022-03-31
MX2022001803A (es) 2022-03-11
CR20220064A (es) 2022-05-04
BR112022001628A2 (pt) 2022-06-21
AU2020328154A1 (en) 2022-03-03
KR20220045978A (ko) 2022-04-13
GEP20247611B (en) 2024-03-11
US20230113037A1 (en) 2023-04-13
PE20220967A1 (es) 2022-06-10
IL290445A (en) 2022-04-01
WO2021028382A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
PH12018502472A1 (en) 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
PH12019501846A1 (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
JOP20220034A1 (ar) مركبات [1، 2، 4] تريازولو [1، 5-جـ] كوينازولين-5-أمين
PH12018550173A1 (en) Pyrazolopyrimidine derivatives
CR20220236A (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
PH12019502851A1 (en) New azaquinoline derivatives
WO2018077944A3 (en) 4,5-annulated 1,2,4-triazolones
MX2021004707A (es) Nuevos compuestos antihelminticos.
PH12020551891A1 (en) New quinoline derivatives
WO2020126968A3 (en) Urea derivatives for use against proliferative diseases
WO2017198341A8 (en) MACROCYCLIC INDOLE DERIVATIVES
MX2019012803A (es) Nuevos derivados de pirazol biciclicos.
PH12020500134A1 (en) Dihydrooxadiazinones
SA518400501B1 (ar) مركبات [8- (فنيل سلفونيل)-3، 8-ديازا ثنائي سيكلو [3. 2. 1] أوكتـ-3-يل] ميثانون (1h-1، 2، 3-تريازول-4-يل)
EA201991835A1 (ru) 2-гетероарил-3-оксо-2,3-дигидропиридазин-4-карбоксамиды для лечения злокачественного новообразования